ReviewMolecular biology reports2026
Translational stem cell therapy for neurodegeneration and CNS trauma: a focused review.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) disorders, including spinal cord injury (SCI) and traumatic brain injury (TBI), often result in severe and irreversible functional impairments due to complex pathophysiological processes such as neuroinflammation, axonal damage, and neuronal cell death. Conventional treatment strategies have shown limited efficacy in restoring neurological function. Stem cell therapy has emerged as a promising avenue for CNS repair, offering potential benefits such as neuronal regeneration, modulation of immune responses, and secretion of neurotrophic factors. Various stem cell types, including neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs), have demonstrated therapeutic potential in the preclinical and early clinical studies for conditions such as TBI, SCI, stroke, Parkinson's disease, and multiple sclerosis. Despite significant progress, challenges such as cell delivery optimization, risk of tumorigenesis, immune compatibility, and ethical concerns must be addressed to enable broader clinical application. This review highlights the recent advances in stem cell-based therapies for CNS disorders, discusses the mechanisms underlying their therapeutic effects, and outlines future directions for research and clinical translation.
Indexed as
Identifiers
42201594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.